Received: 8 January 2022
Accepted: 25 April 2022
First Online: 3 May 2022
: Analysis and use of human subjects were approved by the Ethical Committee of Kyoto University Hospital (approved number: R1721, R1281, R2904 and G1200) and by the Ethical Committee of Sumitomo Pharma (2017–04). Informed consent in writing was obtained from each patient. All experiments have been conducted in accordance with the Declaration of Helsinki as well as the guidelines and regulations of the Committee. All experimental procedures involving animal use for animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Sumitomo Pharma, Co., Ltd., and experiments were conducted in compliance with the ARRIVE guidelines.
: Not applicable.
: SW, TO, HU, JO, and TK are employees of Sumitomo Pharma Co., Ltd. This work was supported in part by research funding from Sumitomo Pharma Co., Ltd.